- Report
- January 2024
- 175 Pages
Global
From €4834EUR$5,000USD£4,155GBP
- Report
- February 2024
- 137 Pages
Global
From €4592EUR$4,750USD£3,947GBP
- Report
- February 2024
- 111 Pages
Global
From €4592EUR$4,750USD£3,947GBP
- Report
- November 2023
- 182 Pages
Global
From €4737EUR$4,900USD£4,071GBP
- Report
- March 2020
- 330 Pages
Global
From €2900EUR$3,000USD£2,493GBP
- Report
- March 2021
- 102 Pages
Global
From €4350EUR$4,500USD£3,739GBP
- Report
- July 2020
- 1740 Pages
Global
From €4640EUR$4,800USD£3,988GBP
Idarubicin is an oncology drug used to treat acute myeloid leukemia (AML). It is a type of anthracycline antibiotic, which works by inhibiting the growth of cancer cells. Idarubicin is administered intravenously and is usually given in combination with other chemotherapy drugs. It is also used to treat other types of cancer, such as lymphoma and multiple myeloma. Idarubicin is generally well tolerated, but can cause side effects such as nausea, vomiting, hair loss, and anemia.
Idarubicin is available in both generic and branded forms. It is marketed by several pharmaceutical companies, including Pfizer, Bristol-Myers Squibb, and Teva Pharmaceuticals. It is also available in combination with other drugs, such as cytarabine and daunorubicin.
The Idarubicin market is highly competitive, with many companies offering similar products. Companies in the market include Pfizer, Bristol-Myers Squibb, Teva Pharmaceuticals, Mylan, Sandoz, and Sun Pharmaceuticals. Show Less Read more
